Li Cheng-Gang, Pu Meng-Fan, Li Chun-Zhu, Gao Man, Liu Ming-Xia, Yu Cun-Zhi, Yan Hong, Peng Chun, Zhao Yang, Li Yu, Ma Ze-Long, Qi Xin-Ming, Wang Yi-Zheng, Miao Ling-Ling, Ren Jin
Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Beijing 100049, China.
Acta Pharmacol Sin. 2017 Jan;38(1):110-119. doi: 10.1038/aps.2016.92. Epub 2016 Sep 19.
Previous studies have shown that microRNA-1304 (miR-1304) is dysregulated in certain types of cancers, including non-small cell lung cancer (NSCLC), and might be involved in tumor survival and/or growth. In this study we investigated the direct target of miR-1304 and its function in NSCLC in vitro. Human lung adenocarcinoma cell lines (A549 and NCI-H1975) were studied. The cell proliferation and survival were investigated via cell counting, MTT and colony-formation assays. Cell apoptosis and cell cycle were examined using annexin V-PE/7-AAD and PI staining assays, respectively. The dual-luciferase reporter assay was used to verify post-transcriptional regulation of heme oxygenase-1 (HO-1) by miR-1304. CRISPR/Cas9 was used to deplete endogenous miR-1304. Overexpression of MiR-1304 significantly decreased the number and viability of NSCLC cells and colony formation, and induced cell apoptosis and G/G phase cell cycle arrest. HO-1 was demonstrated to be a direct target of miR-1304 in NSCLC cells. Restoration of HO-1 expression by hemin (20 μmol/L) abolished the inhibition of miR-1304 on cell growth and rescued miR-1304-induced apoptosis in A549 cells. Suppression of endogenous miR-1304 with anti-1304 significantly increased HO-1 expression and promoted cell growth and survival in A549 cells. In 17 human NSCLC tissue samples, miR-1304 expression was significantly decreased, while HO-1 expression was significantly increased as compared to normal lung tissues. MicroRNA-1304 is a tumor suppressor and HO-1 is its direct target in NSCLC. The results suggest the potential for miR-1304 as a therapeutic target for NSCLC.
先前的研究表明,微小RNA-1304(miR-1304)在某些类型的癌症中表达失调,包括非小细胞肺癌(NSCLC),并且可能参与肿瘤的存活和/或生长。在本研究中,我们在体外研究了miR-1304的直接靶点及其在NSCLC中的功能。我们研究了人肺腺癌细胞系(A549和NCI-H1975)。通过细胞计数、MTT和集落形成试验研究细胞增殖和存活情况。分别使用膜联蛋白V-PE/7-AAD和PI染色试验检测细胞凋亡和细胞周期。使用双荧光素酶报告基因试验验证miR-1304对血红素加氧酶-1(HO-1)的转录后调控。使用CRISPR/Cas9敲除内源性miR-1304。MiR-1304的过表达显著降低了NSCLC细胞的数量和活力以及集落形成,并诱导细胞凋亡和G/G期细胞周期阻滞。HO-1被证明是NSCLC细胞中miR-1304的直接靶点。用血红素(20μmol/L)恢复HO-1表达消除了miR-1304对细胞生长的抑制作用,并挽救了miR-1304诱导的A549细胞凋亡。用抗-1304抑制内源性miR-1304显著增加了HO-1表达,并促进了A549细胞的生长和存活。在17例人NSCLC组织样本中,与正常肺组织相比,miR-1304表达显著降低,而HO-1表达显著增加。微小RNA-1304是一种肿瘤抑制因子,HO-1是其在NSCLC中的直接靶点。结果表明miR-1304作为NSCLC治疗靶点的潜力。